- Home
- GLPG vs WT Comparison
GLPG vs WT Comparison
Compare GLPG & WT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | WT |
|---|---|---|
| Founded | 1999 | 1985 |
| Country | Belgium | United States |
| Employees | 704 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GLPG | WT |
|---|---|---|
| Price | $29.98 | $14.59 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $36.50 | $16.75 |
| AVG Volume (30 Days) | 150.8K | ★ 2.2M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.86% |
| EPS Growth | N/A | ★ 127.27 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $493,753,000.00 |
| Revenue This Year | N/A | $35.32 |
| Revenue Next Year | N/A | $8.08 |
| P/E Ratio | ★ N/A | $18.53 |
| Revenue Growth | N/A | ★ 15.43 |
| 52 Week Low | $22.59 | $7.47 |
| 52 Week High | $37.78 | $17.68 |
Technical Indicators
Market Signals| Indicator | GLPG | WT |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 46.30 |
| Support Level | $28.78 | $13.07 |
| Resistance Level | $33.67 | $14.96 |
| Average True Range (ATR) | 0.86 | 0.58 |
| MACD | -0.28 | -0.04 |
| Stochastic Oscillator | 30.85 | 58.44 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About WT WisdomTree Inc.
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.